The research conducted by GME predicted that the Global Vaccine Adjuvants Market will expand at a high CAGR value from 2020 to 2026. Adjuvants help the individuals receiving vaccines to develop a strong response to the vaccines. Adjuvants are clinically tested and are under constant clinical trials to increase immunogenicity. Adjuvants are useful in reducing the dose of antigen needed, and also reduce the costs and need for booster shots. Increasing grants, partnerships among manufacturers to supply adjuvanted vaccine for COVID-19, and government subsidies for the supply of vaccine adjuvant will accentuate the market demand.
Browse 153 Market Data Tables and 113 Figures spread through 183 Pages and in-depth TOC on "Vaccine Adjuvants Market - Forecast to 2026"
By Product Type (Particulate Adjuvants, Adjuvant Emulsions, Pathogen Components, Combination Adjuvants, Others), By Route of Administration (Intramuscular Route, Subcutaneous Route, Intranasal Route, Oral Route, Intradermal Route, Others), By Disease Type (Infectious Diseases, Cancer, Others) By Application (Research Application, Commercial Application), By Application Category (Human Vaccine Adjuvants, Veterinary Vaccine Adjuvants), By Region (North America, Asia Pacific, Europe, Central & South America, Middle East & Africa); End-User Landscape, Company Market Share Analysis, and Competitor Analysis
Key Market Insights:
· Particulate adjuvant will occupy a significant and dominant market share
· The subcutaneous route remains the ideal choice for the delivery of vaccines by using the syringe and needles.
· Serum Institute, Glaxo SmithKline, Sinovac Life Sciences, VBI Vaccines, ViroVax, SEPPIC, Invivogen, and Dynavax are key players operating in this market space.
Browse the Report @ https://www.globalmarketestimates.com/market-report/global-vaccine-adjuvants-market-2832
Product Outlook (Revenue, USD Million, 2021 - 2026)
· Particulate Adjuvants
· Adjuvant Emulsions
· Pathogen Components
· Combination Adjuvants
Route of Administration Outlook (Revenue, USD Million, 2021-2026)
· Intramuscular Route
· Subcutaneous Route
· Intranasal Route
· Oral Route
· Intradermal Route
Disease Type Outlook (Revenue, USD Million, 2021 - 2026)
· Infectious Disease
Application Outlook (Revenue, USD Million, 2021 - 2026)
· Research Application
· Commercial Application
Application Category Outlook (Revenue, USD Million, 2021 - 2026)
· Human Vaccine Adjuvants
· Veterinary Vaccine Adjuvants
Regional Outlook (Revenue, USD Million, 2021 - 2026)
· Rest of Europe
· South Korea
· Rest of APAC
Central & South America
· Rest of CSA
Middle East & Africa
· Saudi Arabia
· South Africa
· Rest of MEA
Contact: Tracy Simon
Email address: firstname.lastname@example.org
Phone Number: +16026667238
Check our Latest Blogs: https://www.globalmarketestimates.com/blog-posts.php
Next-Gen Expertise About Us
Vaccine Adjuvants Market Insight
Adjuvants help the individuals receiving vaccines to develop a strong response to the vaccines.
Adjuvants are clinically tested and are under constant clinical trials to increase immunogenicity.
Adjuvants are useful in reducing the dose of antigen needed, and also reduce the costs and need for
booster shots. Infants receiving the vaccine adjuvants benefit by way of enhanced immune reactions.
The use of adjuvants in vaccines has persisted for over 70 years. The efficacy of the adjuvants is
predetermined in the clinical trials before the licensing of the vaccines. Continous evaluation, ongoing
research are supporting the use of adjuvants in vaccines meant for the mass population.
Citing some of the adjuvants, the use of aluminum salts in vaccines has persisted since the 1930s and
it has been used with tetanus and diphtheria vaccines. MF59 is another adjuvant used in the influenza
vaccine-Flaud which is licensed to be used in Europe and the USA. The newly manufactured adjuvant
CpG 1018 has been used in the Heplisav-B vaccine. This adjuvant has also secured wide-scale
investment from top biopharmaceutical players. In 2021, CEPI and Dynavax decided to invest $99
million to increase the manufacturing of CpG 1018. Partnerships and alliances among vaccine
developers are also boosting the market demand for Cpg1018 adjuvants. Other adjuvants, AS01?B are
also being further clinically tested for the vaccines of HIV and malaria. Manufacturers are also
expanding the market for AS01B adjuvant by starting the phase 2a trials for the AS01B adjuvant.
COVID-19 has created a market of its own, as adjuvant CpG1018 is supplied to fulfill the demand for
the COVID-19 vaccine. Manufacturers are participating in deals to supply the required adjuvant for the
COVID-19 vaccine and also storing it in bulk to helps advance the production of the vaccine for COVID-